Adherence to the treatment of pa­tients in the long-term supervision period after myocardial infarction (according to the REGATA register)

Aim To study long-term compliance with treatment in patients included into the REGistry of pATients after myocArdial infarction (REGATA).
Material and methods In 2012–2013, the study included 481 patients with a history of myocardial infarction (MI) who visited the district outpatient clinic. Median age was 72 [62;78] years; men, 51.4 % (n=247); median time from the last MI to the date of inclusion into the registry was 5 [2;9] years. Compliance with treatment was determined with the Morisky-Green questionnaire during telephone contacts with patients at 36 and 48 months (n=230) after the inclusion. Patients scored 4 were considered compliant; patients scored 3 were low-compliant; and patients scored 0-2 were non-compliant. Statistical significance of differences in compliance at 36 and 48 months was assessed with the McNemar test.
Results There were no significant differences between the proportions of compliant, low-compliant and non-compliant patients for the analyzed period. However, at 48 months after the inclusion, the number of patients who had difficulties in answering the questionnaire questions significantly increased from 15.5 % to 21.6 % (p=0.04). Analysis of changes in compliance with the treatment for only compliant patients showed that at 36 months from the inclusion, 87 patients remained highly compliant (37.8 %) while at 48 months, only 32 (36.8 %) patients remained compliant with the treatment. Proportion of compliant patients did not significantly differ for men and women, patients younger and older than 60 years, patients with primary MI and reinfarction, prone and not prone to self-management, and for those who used or not the medicine assistance.
Conclusion The data obtained as a part of the REGATA registry indicate insufficient long-term compliance with the treatment of after-MI patients with both primary MI and reinfarction, an increasing proportion of patients who are unable to assess their degree of compliance, and decreasing compliance among highly compliant patients during the period between 36 and 48 months of observation. On the whole, there were no significant changes in the compliance with the treatment for 12 months between the first and the second interviews. The proportion of patients compliant with the prescribed drug therapy was significantly lower in the presence of predisposition to self-management.

1. Virtanen M, Ervasti J, Mittendorfer-Rutz E, Lallukka T, Kjeldgård L, Friberg E et al. Work disability before and after a major cardiovascular event: a ten-year study using nationwide medical and insurance registers. Scientific Reports. 2017;7(1):1142. DOI: 10.1038/s41598-017-01216-2

2. Walker IF, Garbe F, Wright J, Newell I, Athiraman N, Khan N et al. The Economic Costs of Cardiovascular Disease, Diabetes Mellitus, and Associated Complications in South Asia: A Systematic Review. Value in Health Regional Issues. 2018;15:12–26. DOI: 10.1016/j.vhri.2017.05.003

3. NICE. Statins for the prevention of cardiovascular events. Technology appraisal guidance [TA94]. [Internet] Available at: https://www.nice.org.uk/guidance/ta94

4. Kontsevaya A.V., Drapkina O.M., Balanova Yu.A., Imaeva A.E., Suvorova E.I., Khudyakov M.B. Economic Burden of Cardiovascular Diseases in the Russian Federation in 2016. Rational Pharmacotherapy in Cardiology. 2018;14(2):156–66. DOI: 10.20996/1819-6446-201814-2-156-166

5. Tuppin P, Rivière S, Rigault A, Tala S, Drouin J, Pestel L et al. Prevalence and economic burden of cardiovascular diseases in France in 2013 according to the national health insurance scheme database. Archives of Cardiovascular Diseases. 2016;109(6–7):399–411. DOI: 10.1016/j.acvd.2016.01.011

6. Lakic D, Tasic L, Kos M. Economic burden of cardiovascular diseases in Serbia. Vojnosanitetski pregled. 2014;71(2):137–43. DOI: 10.2298/VSP1402137L

7. Alekyan B.G., Grigor’yan A.M., Staferov A.V., Karapetyan N.G. Endovascular diagnostics and treatment in the Russian Federation (2017). Russian Journal of Endovascular Surgery. 2018;5(2):93– 240.

8. Ulanova N.N., Yakovleva N.V. Features of healthy-preserving behavior and adherence to treatment by doctors at different stages of professional development. I.P. Pavlov Russian Medical Biological Herald. 2015;23(1):102–8. DOI: 10.17816/PAVLOVJ20151102-108

9. Lukina Yu.V., Kutishenko N.P., Dmitrieva N.A., Martsevich S.Yu. Сompliance to clinician prescriptions in ischemic heart disease patients (by the data from outpatient registry PROFILE). Russian Journal of Cardiology. 2017;22(3):14–9. DOI: 10.15829/1560-4071-2017-3-14-19

10. Nelidova A.V., Usacheva E.V., Zamakhina O.V., Suprun E.V. Influencing factors for adherence to treatmentof patients with coronary atherosclerosis in the long term vascular events. Modern problems of science and education. 2015;4:364.

11. Pereverzeva K.G., Seleznev S.V., Vorobiev A.N., Moseichuk K.A., Lukyanov M.M., Lukina Yu.V. Adherence to the treatment of patients with ischemic heart disease according to the register of cardiovascular diseases (RECVAZA). Science of young (Eruditio Juvenium). 2017;5(1):14–21. DOI: 10.23888/HMJ2017114-21

12. Garganeeva A.A., Kuzheleva E.A., Tukish O.V. The role of treatment adherence after myocardial infarction (according to the acute myocardial infarction registry). Complex Issues of Cardiovascular Diseases. 2019;8(4):56–64. DOI: 10.17802/2306-1278-2019-8-4-56-64

13. Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association of Statin Adherence with Mortality in Patients with Atherosclerotic Cardiovascular Disease. JAMA Cardiology. 2019;4(3):206–13. DOI: 10.1001/jamacardio.2018.4936

14. Gibbons RJ, Miller TD. Optimal Medical Therapy for Known Coronary Artery Disease: A Review. JAMA Cardiology. 2017;2(9):1030–5. DOI: 10.1001/jamacardio.2017.2249

15. Choudhry NK, Avorn J, Glynn RJ, Antman EM, Schneeweiss S, Toscano M et al. Full Coverage for Preventive Medications after Myocardial Infarction. New England Journal of Medicine. 2011;365(22):2088–97. DOI: 10.1056/NEJMsa1107913

16. Ministry of Health of Russian Federation. Order of the Ministry of health of the Russian Federation of January 9, 2020 N 1N “On approval of the list of medicines for medical use to provide for one year in outpatient conditions for persons who have suffered an acute violation of cerebral circulation, myocardial infarction, as well as who have undergone coronary artery bypass grafting, angioplasty with stenting and catheter ablation for cardiovascular diseases». Av. at: http://base.garant.ru/73462529/.

17. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Medical Care. 1986;24(1):67–74. PMID: 3945130

18. Pereverzeva K.G., Loukianov M.M., С. Ю. Марцевич, Andreenko E.Yu., А. В. Загребельный, Boytsov S.A. et al. Long-term adherence to treatment in patients with ischemic heart disease and myocardial infarction in comparison with other cardiovascular diseases. Therapy. 2019;5(1 (27)):54–9. DOI: 10.18565/therapy.2019.1.54-59

19. Loukianov M.M., Kozminsky A.N., Martsevich S.Yu., Yakushin S.S., Vorobyev A.N., Zagrebelnyy A.V. et al. Patients with combination of chronic heart failure, hypertension and history of myocardial infarction: clinical and anamnestic characteristics, administration of ace inhibitors, angiotensin receptor blockers, -blockers and adherence to the drug therapy (data of outpatient registry RECVASA). Rational Pharmacotherapy in Cardiology. 2017;13(2):207–12. DOI: 10.20996/1819-6446-2017-13-2-207-212

20. Davidovich I.M., Malay L.N., Kutishenko N.P. The analysis of longterm outcomes and adherent to treatment in patients after myocardial infarction: Khabarovsk Register Data. The Clinician. 2017;11(1):36– 44. DOI: 10.17650/1818-8338-2016-10-4-36-44

21. Sedykh D.Yu., Petrov G.P., Kashtalap V.V. Differences in adherence behaviour patterns in patients with primary and recurrent myocardial infarction. Complex Issues of Cardiovascular Diseases. 2018;7(4):15– 25. DOI: 10.17802/2306-1278-2018-7-4-15-25

22. Martsevich S.Yu., Semenova Yu.V., Kutishenko N.P., Zagebelnyy A.A., Ginzburg M.L. Assessment of patients compliance for ambulatory institutions visits and its influence on the quality of treatment before development of acute coronary syndrome, by the LIS-3 registry. Russian Journal of Cardiology. 2016;21(6):55–60. DOI: 10.15829/1560-4071-2016-6-55-60

23. Russian scientific medical society of therapists. National recommendations of the Russian scientific medical society of therapists on quantitative assessment of treatment adherence. - Moscow, 2017. Av. at: www.rnmot.ru/public/uploads/RNMOT/clinical/2017/Национальные рекомендации.pdf.